SCYNEXIS (LTS:0L49) ROCE % : 4.52% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SCYNEXIS's annualized ROCE % for the quarter that ended in Mar. 2024 was 4.52%.

SCYNEXIS ROCE % Historical Data

The historical data trend for SCYNEXIS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS ROCE % Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-112.86

-93.48

-36.51

-70.64

77.14

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-273.54	604.88	-4.57	-63.07	4.52

SCYNEXIS ROCE % Calculation

SCYNEXIS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	70.309	/	( ( (87.81 - 17.618)	+	(128.412 - 16.303) )	/ 2 )
	=	70.309	/	( (70.192	+	112.109)	/ 2 )
	=	70.309	/	91.1505
	=	77.14 %

SCYNEXIS's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	4.588	/	( ( (128.412 - 16.303)	+	(118.254 - 27.349) )	/ 2 )
	=	4.588	/	( ( 112.109	+	90.905 )	/ 2 )
	=	4.588	/	101.507
	=	4.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

SCYNEXIS (LTS:0L49) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SCYNEXIS ROCE % Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines